Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease

Da-Bin Ryu,Ji-Young Lim,Tae-Woo Kim, Seoho Shin,Sung-Eun Lee,Gyeongsin Park,Chang-Ki Min

Experimental Hematology（2021）

引用 7|浏览0

暂无评分

摘要

•The pharmacologic activity of ruxolitinib, a JAK1/2 inhibitor, was investigated in a preclinical scl-GVHD model.•Ruxolitinib regulated activation, proliferation, and migration of immune effector cells in vitro and in vivo.•Ruxolitinib can prevent scl-GVHD via inhibition of JAK/STAT1 signaling in the immune effector cells.

查看译文

关键词

JAK-STAT signaling,JAK1/2 inhibitor,T cells,macrophages,sclerodermatous cGVHD

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要